

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Scott Anthony Richards
Date of last notice	1 September 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C> as nominee for Scott Richards (1) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards (2) HSBC Nominees (Australia) Limited as nominee for Scott Anthony Richards & Susan Marie Richards <Northumberland Trust> (3)
Date of change	4 Dec 2020
No. of securities held prior to change	20,225,915 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 2,555,805 Performance Rights pursuant to Performance Right and Option Plan
Class	Ordinary Shares & Performance Rights
Number acquired	8,643,782 Ordinary Shares pursuant to the Executive Share Loan Scheme 1,125,492 Performance Rights pursuant to the Performance Rights and Option Plan
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Loan Shares acquired at \$0.3554 (acquisition price being the weighted average price of Mayne Pharma fully paid ordinary shares in the 5 days from 24 November to 30 November) Performance Rights - Nil

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	28,869,697 Ordinary Shares pursuant to Executive Share Loan Scheme (1) 3,862,906 Ordinary Shares (2) 1,722,463 Ordinary Shares (3) 3,681,297 Performance Rights pursuant to Performance Right and Option Plan
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of loan shares and performance rights pursuant to Resolution 4 in the Notice of Meeting for the Company's 2020 Annual General Meeting.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/a
If prior written clearance was provided, on what date was this provided?	N/a

+ See chapter 19 for defined terms.